AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO)

zzlangerhans (99.78) Submitted: 9/25/2010 8:34:52 AM : Start Price: $9.00 AVEO Score: +10.92

AVEO is up more than 50% in less than a month to an all-time high on low volume and no catalysts. I doubt we'll see a major catalyst before topline data from the phase III trial of TIVO-1 in renal cell carcinoma in mid-2011. Most of the optimism for TIVO-1 comes from its performance in an uncontrolled phase II trial, with progression-free survival measured against historical standards. Sounds like a story I've heard many times before. In the meantime, broad market downdrafts are sure to pressure AVEO at their current lofty valuation.